$CTMX
CytomX Therapeutics Inc

2022 Q4 Form 10-Q Financial Statement

#000095017022023190 Filed on November 08, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $946.0K $16.92M $17.59M
YoY Change -95.2% -3.82% -1.13%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $10.07M $10.49M $11.09M
YoY Change 6.46% -5.37% 28.45%
% of Gross Profit
Research & Development $19.56M $30.37M $29.14M
YoY Change -46.52% 4.2% 21.18%
% of Gross Profit
Depreciation & Amortization $608.0K $623.0K $680.0K
YoY Change -9.93% -8.38% 13.33%
% of Gross Profit
Operating Expenses $29.63M $40.86M $40.23M
YoY Change -35.63% 1.56% 23.09%
Operating Profit -$23.94M -$22.64M
YoY Change 5.75% 52.0%
Interest Expense $732.0K $616.0K $70.00K
YoY Change 902.74% 780.0% -65.0%
% of Operating Profit
Other Income/Expense, Net $1.000K $30.00K -$13.00K
YoY Change -85.71% -330.77% -13.33%
Pretax Income -$27.95M -$23.30M -$22.58M
YoY Change 6.57% 3.15% 53.53%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$27.95M -$23.30M -$22.58M
YoY Change 6.57% 3.15% 53.53%
Net Earnings / Revenue -2954.76% -137.72% -128.41%
Basic Earnings Per Share
Diluted Earnings Per Share -$0.42 -$353.4K -$346.3K
COMMON SHARES
Basic Shares Outstanding 66.08M 65.95M 65.16M
Diluted Shares Outstanding 65.91M 65.21M

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $193.7M $194.3M $236.3M
YoY Change -36.56% -17.77% -26.41%
Cash & Equivalents $193.7M $95.04M $236.3M
Short-Term Investments $0.00 $99.25M $5.000K
Other Short-Term Assets $7.466M $4.278M $3.822M
YoY Change 74.24% 11.93% -31.75%
Inventory
Prepaid Expenses
Receivables $35.99M $1.712M $887.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $237.1M $200.3M $241.0M
YoY Change -23.59% -16.9% -29.18%
LONG-TERM ASSETS
Property, Plant & Equipment $5.072M $5.710M $6.271M
YoY Change -14.9% -8.95% -79.37%
Goodwill $949.0K $949.0K $949.0K
YoY Change 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments $99.97M
YoY Change
Other Assets $27.00K $895.0K $902.0K
YoY Change -97.0% -0.78% -60.78%
Total Long-Term Assets $23.79M $26.21M $130.2M
YoY Change -18.28% -79.87% 273.17%
TOTAL ASSETS
Total Short-Term Assets $237.1M $200.3M $241.0M
Total Long-Term Assets $23.79M $26.21M $130.2M
Total Assets $260.9M $226.5M $371.2M
YoY Change -23.13% -38.99% -1.06%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.809M $5.176M $1.516M
YoY Change -0.32% 241.42% -57.89%
Accrued Expenses $28.53M $31.34M $25.17M
YoY Change -16.66% 24.53% 5.1%
Deferred Revenue $121.3M $61.33M $73.09M
YoY Change 75.08% -16.1%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $152.6M $97.84M $99.77M
YoY Change 43.54% -1.94% -2.18%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $194.0M $100.2M $159.8M
YoY Change 35.01% -37.31% -29.02%
Total Long-Term Liabilities $194.0M $100.2M $159.8M
YoY Change 35.01% -37.31% -29.02%
TOTAL LIABILITIES
Total Short-Term Liabilities $152.6M $97.84M $99.77M
Total Long-Term Liabilities $194.0M $100.2M $159.8M
Total Liabilities $346.6M $198.0M $259.6M
YoY Change 38.64% -23.71% -20.65%
SHAREHOLDERS EQUITY
Retained Earnings -$722.9M -$605.1M -$507.5M
YoY Change 35.44% 19.23%
Common Stock $1.000K $1.000K $1.000K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$85.75M $28.47M $111.7M
YoY Change
Total Liabilities & Shareholders Equity $260.9M $226.5M $371.2M
YoY Change -23.13% -38.99% -1.06%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$27.95M -$23.30M -$22.58M
YoY Change 6.57% 3.15% 53.53%
Depreciation, Depletion And Amortization $608.0K $623.0K $680.0K
YoY Change -9.93% -8.38% 13.33%
Cash From Operating Activities -$1.394M -$33.84M -$29.70M
YoY Change -95.53% 13.95% 20.24%
INVESTING ACTIVITIES
Capital Expenditures $182.0K -$410.0K -$268.0K
YoY Change -174.29% 52.99% -66.5%
Acquisitions
YoY Change
Other Investing Activities $100.0M $0.00 $10.00M
YoY Change -100.0% -111.2%
Cash From Investing Activities $99.82M -$410.0K $9.734M
YoY Change -40842.04% -104.21% -110.8%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 190.0K 0.000 104.0K
YoY Change -72.18% -100.0% -48.0%
NET CHANGE
Cash From Operating Activities -1.394M -33.84M -29.70M
Cash From Investing Activities 99.82M -410.0K 9.734M
Cash From Financing Activities 190.0K 0.000 104.0K
Net Change In Cash 98.61M -34.25M -19.86M
YoY Change -420.65% 72.46% -82.67%
FREE CASH FLOW
Cash From Operating Activities -$1.394M -$33.84M -$29.70M
Capital Expenditures $182.0K -$410.0K -$268.0K
Free Cash Flow -$1.576M -$33.43M -$29.43M
YoY Change -94.91% 13.6% 23.15%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2022#LicenseAndServiceMember
dei Entity Central Index Key
EntityCentralIndexKey
0001501989
CY2021Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2022#LicenseAndServiceMember
CY2022Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2022#LicenseAndServiceMember
CY2022Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2022#LicenseAndServiceMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2022#LicenseAndServiceMember
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2022#LicenseAndServiceMember
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2022#LicenseAndServiceMember
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2022#LicenseAndServiceMember
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37587
dei Entity Registrant Name
EntityRegistrantName
CytomX Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-3521219
dei Entity Address Address Line1
EntityAddressAddressLine1
151 Oyster Point Blvd.
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 400
dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1468000
CY2022Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
61325000
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
CY2022Q3 us-gaap Assets
Assets
226492000
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
66084367
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
95036000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
205530000
CY2022Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
99254000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
99696000
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1712000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
790000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4278000
CY2021Q4 us-gaap Assets
Assets
339411000
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
5176000
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
515-3185
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2818000
dei Security12b Title
Security12bTitle
Common Stock, $0.00001 par value per share
dei Trading Symbol
TradingSymbol
CTMX
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
31340000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
34236000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4285000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
200280000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
310301000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5710000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5960000
CY2022Q3 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
911000
CY2021Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
1021000
CY2022Q3 us-gaap Goodwill
Goodwill
949000
CY2021Q4 us-gaap Goodwill
Goodwill
949000
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
917000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
917000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
16830000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
19362000
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
895000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
901000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
69262000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
97841000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
106316000
CY2022Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
85122000
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
125660000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
15055000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
18056000
CY2022Q3 us-gaap Liabilities
Liabilities
198018000
CY2021Q4 us-gaap Liabilities
Liabilities
250032000
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
65950242
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
65950242
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
65392758
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
65392758
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
1000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
634357000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
623344000
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-795000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-242000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-605089000
us-gaap Operating Income Loss
OperatingIncomeLoss
-72650000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-533724000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
28474000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
89379000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
226492000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
339411000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
16915000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
17587000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
52217000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
49846000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30367000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29143000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
92085000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
77615000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10490000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11085000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
32782000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
29704000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
40857000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
40228000
us-gaap Operating Expenses
OperatingExpenses
124867000
us-gaap Operating Expenses
OperatingExpenses
107319000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-23942000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-22641000
us-gaap Operating Income Loss
OperatingIncomeLoss
-57473000
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
616000
CY2021Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
70000
us-gaap Investment Income Interest
InvestmentIncomeInterest
946000
us-gaap Investment Income Interest
InvestmentIncomeInterest
182000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
30000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-13000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
339000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-90000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-23296000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-22584000
us-gaap Net Income Loss
NetIncomeLoss
-71365000
us-gaap Net Income Loss
NetIncomeLoss
-57381000
CY2022Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
367000
CY2021Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
37000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-553000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
99000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22929000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22547000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-71918000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-57282000
CY2022Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.35
CY2022Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.35
CY2021Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.35
CY2021Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.35
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-1.09
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-1.09
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.90
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.90
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
65912334
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
65912334
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
65208066
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
65208066
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
65618162
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
65618162
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
63759585
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
63759585
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
89379000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
7000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3370000
CY2022Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-677000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-23885000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
68194000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
91000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
360000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4490000
CY2022Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-243000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-24184000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
48708000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2695000
CY2022Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
367000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-23296000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
28474000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
49803000
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
107712000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1023000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3034000
CY2021Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
4000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-15554000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
146022000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
173000
CY2021Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
518000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3425000
CY2021Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
58000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-19243000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
130953000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
104000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3164000
CY2021Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
37000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-22584000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
111674000
us-gaap Profit Loss
ProfitLoss
-71365000
us-gaap Profit Loss
ProfitLoss
-57381000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
110000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
110000
ctmx Depreciation And Amortization Excluding Amortization Of Intangible Assets
DepreciationAndAmortizationExcludingAmortizationOfIntangibleAssets
1725000
ctmx Depreciation And Amortization Excluding Amortization Of Intangible Assets
DepreciationAndAmortizationExcludingAmortizationOfIntangibleAssets
1921000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
47000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-287000
us-gaap Share Based Compensation
ShareBasedCompensation
10555000
us-gaap Share Based Compensation
ShareBasedCompensation
9623000
ctmx Noncash Lease Expense
NoncashLeaseExpense
-2532000
ctmx Noncash Lease Expense
NoncashLeaseExpense
-2325000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
986000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
89000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-7000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3274000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-6000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-1270000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2441000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1358000
ctmx Increase Decrease In Accrued And Other Liabilities Noncurrent
IncreaseDecreaseInAccruedAndOtherLiabilitiesNoncurrent
-5897000
ctmx Increase Decrease In Accrued And Other Liabilities Noncurrent
IncreaseDecreaseInAccruedAndOtherLiabilitiesNoncurrent
-550000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-48475000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-47271000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-109394000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-87839000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1558000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1364000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
0
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
99898000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
0
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
123996000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1558000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
22734000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
107712000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
458000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1818000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
458000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
109530000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-110494000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
44425000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
206447000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
192776000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
95953000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
237201000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
205530000
CY2022Q3 ctmx Accrued Research And Clinical Current
AccruedResearchAndClinicalCurrent
15252000
us-gaap Nature Of Operations
NatureOfOperations
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1. Description of the Business</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CytomX Therapeutics, Inc. (the “Company”) is a clinical-stage, oncology-focused biopharmaceutical company dedicated to destroying cancer differently. The Company aims to build a commercial enterprise to maximize its impact on the treatment of cancer. The Company is advancing potential first-in-class and best-in-class antibody-based therapeutics created using its Probody® therapeutic technology platform that could meaningfully improve outcomes for cancer patients. Its proprietary and unique Probody technology platform is designed to enable “conditional activation” of antibody-based drugs in the tumor microenvironment while minimizing drug activity in healthy tissues and in circulation. The Company is located in South San Francisco, California and was incorporated in the state of Delaware in September 2010.</span></p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</span></p>
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
95036000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
236284000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
191859000
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
917000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
917000
CY2021Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
917000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
917000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
95953000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
206447000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
237201000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
192776000
CY2022Q3 ctmx Cash Cash Equivalents And Investments Amortized Cost Basis
CashCashEquivalentsAndInvestmentsAmortizedCostBasis
177230000
CY2022Q3 ctmx Cash Cash Equivalents And Short Term Investments Accumulated Gross Unrealized Loss Before Tax
CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLossBeforeTax
795000
CY2022Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
176435000
CY2021Q4 ctmx Cash Cash Equivalents And Investments Amortized Cost Basis
CashCashEquivalentsAndInvestmentsAmortizedCostBasis
266591000
CY2021Q4 ctmx Cash Cash Equivalents And Short Term Investments Accumulated Gross Unrealized Loss Before Tax
CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLossBeforeTax
242000
CY2021Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
266349000
CY2021Q4 ctmx Accrued Research And Clinical Current
AccruedResearchAndClinicalCurrent
18861000
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6325000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
9576000
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1742000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
14261417
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.71
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3961000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3618000
CY2022Q3 us-gaap Restructuring Reserve
RestructuringReserve
3876000
CY2021Q4 us-gaap Restructuring Reserve
RestructuringReserve
0
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
184000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
713000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
31340000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
34236000
CY2022Q3 us-gaap Revenues
Revenues
16915000
CY2021Q3 us-gaap Revenues
Revenues
17587000
us-gaap Revenues
Revenues
52217000
us-gaap Revenues
Revenues
49846000
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
194922000
ctmx Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
0
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
-48475000
CY2022Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
146447000
CY2022Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
146400000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
12192216
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.42
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
4962418
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.94
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
100990
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.98
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
2792227
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.95
CY2022Q3 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.40
CY2022Q3 us-gaap Share Based Compensation
ShareBasedCompensation
200000
CY2022Q3 us-gaap Restructuring Charges
RestructuringCharges
7146000
CY2022Q3 us-gaap Payments For Restructuring
PaymentsForRestructuring
3119000
CY2022Q3 us-gaap Restructuring Reserve Translation And Other Adjustment
RestructuringReserveTranslationAndOtherAdjustment
-151000
CY2022Q3 us-gaap Restructuring Reserve
RestructuringReserve
3876000
CY2022Q3 us-gaap Restructuring Costs
RestructuringCosts
7900000

Files In Submission

Name View Source Status
0000950170-22-023190-index-headers.html Edgar Link pending
0000950170-22-023190-index.html Edgar Link pending
0000950170-22-023190.txt Edgar Link pending
0000950170-22-023190-xbrl.zip Edgar Link pending
ctmx-20220930.htm Edgar Link pending
ctmx-20220930.xsd Edgar Link pending
ctmx-ex10_1.htm Edgar Link pending
ctmx-ex10_2.htm Edgar Link pending
ctmx-ex10_3.htm Edgar Link pending
ctmx-ex10_4.htm Edgar Link pending
ctmx-ex10_5.htm Edgar Link pending
ctmx-ex10_6.htm Edgar Link pending
ctmx-ex31_1.htm Edgar Link pending
ctmx-ex31_2.htm Edgar Link pending
ctmx-ex32_1.htm Edgar Link pending
ctmx-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
ctmx-20220930_lab.xml Edgar Link unprocessable
ctmx-20220930_pre.xml Edgar Link unprocessable
ctmx-20220930_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
ctmx-20220930_htm.xml Edgar Link completed
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ctmx-20220930_cal.xml Edgar Link unprocessable